Macular Hole Progression following Ocriplasmin Intravitreal Injection

Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she s...

Descripción completa

Detalles Bibliográficos
Autores principales: Casswell, Edward, Fernandez-Sanz, Guillermo, Mitry, Danny, Luk, Sheila, Zakir, Rahila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279821/
https://www.ncbi.nlm.nih.gov/pubmed/25580329
http://dx.doi.org/10.1155/2014/403461
_version_ 1782350767938600960
author Casswell, Edward
Fernandez-Sanz, Guillermo
Mitry, Danny
Luk, Sheila
Zakir, Rahila
author_facet Casswell, Edward
Fernandez-Sanz, Guillermo
Mitry, Danny
Luk, Sheila
Zakir, Rahila
author_sort Casswell, Edward
collection PubMed
description Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity.
format Online
Article
Text
id pubmed-4279821
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-42798212015-01-11 Macular Hole Progression following Ocriplasmin Intravitreal Injection Casswell, Edward Fernandez-Sanz, Guillermo Mitry, Danny Luk, Sheila Zakir, Rahila Case Rep Ophthalmol Med Case Report Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity. Hindawi Publishing Corporation 2014 2014-12-14 /pmc/articles/PMC4279821/ /pubmed/25580329 http://dx.doi.org/10.1155/2014/403461 Text en Copyright © 2014 Edward Casswell et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Casswell, Edward
Fernandez-Sanz, Guillermo
Mitry, Danny
Luk, Sheila
Zakir, Rahila
Macular Hole Progression following Ocriplasmin Intravitreal Injection
title Macular Hole Progression following Ocriplasmin Intravitreal Injection
title_full Macular Hole Progression following Ocriplasmin Intravitreal Injection
title_fullStr Macular Hole Progression following Ocriplasmin Intravitreal Injection
title_full_unstemmed Macular Hole Progression following Ocriplasmin Intravitreal Injection
title_short Macular Hole Progression following Ocriplasmin Intravitreal Injection
title_sort macular hole progression following ocriplasmin intravitreal injection
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279821/
https://www.ncbi.nlm.nih.gov/pubmed/25580329
http://dx.doi.org/10.1155/2014/403461
work_keys_str_mv AT casswelledward macularholeprogressionfollowingocriplasminintravitrealinjection
AT fernandezsanzguillermo macularholeprogressionfollowingocriplasminintravitrealinjection
AT mitrydanny macularholeprogressionfollowingocriplasminintravitrealinjection
AT luksheila macularholeprogressionfollowingocriplasminintravitrealinjection
AT zakirrahila macularholeprogressionfollowingocriplasminintravitrealinjection

Ejemplares similares